Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Third party request |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Assays Completed |
| Study Start Date: | 2013-07-24 |
| Study Made Public: | 2016-10-25 |
Title
Immunogenicity of heterologous boost immunizations with MVA-CMDR, a modified vaccinia Ankara HIV-1 vaccine expressing Env gp 150/gag/pol, in HIV-uninfected volunteers previously immunized with DCVax-001 plus poly-ICLC
Description
CAVD 579 (SSC-0803 or TP 22) is a phase I study to evaluate the safety and immunogenicity of heterologous boost immunizations with MVA-CMDR in HIV-uninfected healthy participants previously immunized with the monoclonal antibody, DCVax-001, plus Hiltonol® in CAVD 264 (DC Vax).
Sign in to see full information about this study and to download study data.
Products
Saline (non-specific) DC-VAX Poly ICLC 2004 MVA-CMDRIntegrated data
BAMA, ICS
Non-integrated data
No non-integrated data is available for this study.